propranolol has been researched along with fk 409 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hiraga, H; Okubo, T; Okumura, K; Suto, N; Yamamoto, T; Yoshida, IM | 1 |
Akimoto, Y; Horinouchi, T; Koike, K; Matsushita, M; Okamoto, T; Shibano, M; Tanaka, Y; Yamaki, F; Yamashita, Y | 1 |
2 other study(ies) available for propranolol and fk 409
Article | Year |
---|---|
Nitric oxide donor FK409 and 8-bromoguanosine-cyclic monophosphate attenuate cardiac contractility assessed by Emax.
Topics: Adrenergic beta-Antagonists; Animals; Coronary Circulation; Cyclic GMP; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Myocardial Contraction; Myocardium; Nitric Oxide Donors; Nitro Compounds; omega-N-Methylarginine; Papaverine; Propranolol; Vasodilation; Vasodilator Agents; Ventricular Function, Left | 2001 |
Nitric oxide (NO) primarily accounts for endothelium-dependent component of beta-adrenoceptor-activated smooth muscle relaxation of mouse aorta in response to isoprenaline.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Aorta; Endothelium, Vascular; Enzyme Inhibitors; Isoproterenol; Male; Mice; Muscle, Smooth, Vascular; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Donors; Nitro Compounds; Oxadiazoles; Propranolol; Quinoxalines; Receptors, Adrenergic, beta; Vasodilation | 2002 |